An experimental gene-based vaccine candidate against SARS-CoV-2 is currently under development at Massachusetts Eye and Ear and Massachusetts General Hospital.
Leading this vaccine program is Luk H. Vandenberghe, PhD, director of the Grousbeck Gene Therapy Center at Massachusetts Eye and Ear and associate professor of ophthalmology at Harvard Medical School.
“There is an extraordinary connection with ophthalmology, which may not be so surprising if you think that Luxturna (voretigene neparvovec-rzyl, Novartis), a breakthrough treatment for retinitis pigmentosa, was the first approved gene
Uncategorized